| Name: | Bendamustine Trihydroxyethyl Dimer Impurity |
| Catalogue No. | VE007301 |
| CAS No. | 1391052-61-1 |
| Molecular Formula | C32H44N6O7 |
| Molecular Weight | 624.73 g/mol |
| Status | In-Stock |
| IUPAC Name | 4-(5-((2-((4-(5-(bis(2-hydroxyethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoyl)oxy)ethyl)(2-hydroxyethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid |
| Synonyms | Bendamustine Deschloro Dimer Impurity |
| Description | Bendamustine Trihydroxyethyl compound Impurity ( CAS No: 1391052-61-1 ) or 4-(5-((2-((4-(5-(bis(2-hydroxyethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoyl)oxy)ethyl)(2-hydroxyethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid is associate impurity of Bendamustine. Bendamustine is employed to treat chronic leukemia (CLL; a kind of cancer of the white blood cells). Bendamustine is additionally accustomed to treating a kind of non-Hodgkins malignant neoplastic disease (NHL: cancer t |
| References | “Sci-Hub | Bendamustine: Rebirth of an Old Drug | 10.1200/Jco.2008.18.7252.” Hkvisa.net, 2022, sci-hub.hkvisa.net/10.1200/jco.2008.18.7252. |
